Dianthus Therapeutics (DNTH) News Today $20.77 -1.50 (-6.74%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest UpdateDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 5,100,000 shares, a growth of 7.8% from the October 15th total of 4,730,000 shares. Approximately 25.2% of the shares of the company are sold short. Based on an average trading volume of 191,600 shares, the days-to-cover ratio is presently 26.6 days.November 19 at 5:57 AM | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1% - Time to Sell?November 15, 2024 | marketbeat.comDianthus Therapeutics’ Strategic Advancements and Accelerated Drug Development Drive ‘Buy’ RatingNovember 14, 2024 | markets.businessinsider.comDianthus Therapeutics: Strategic Positioning and Financial Strength Underpin ‘Buy’ Rating Amidst Key Clinical DevelopmentsNovember 14, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for DNTH FY2024 Earnings?Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for Dianthus Therapeutics in a research report issued on Monday, November 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will poNovember 14, 2024 | marketbeat.comDianthus price target raised to $52 from $48 at OppenheimerNovember 11, 2024 | markets.businessinsider.comDianthus Therapeutics (NASDAQ:DNTH) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday.November 11, 2024 | marketbeat.comOppenheimer Boosts Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $52.00Oppenheimer upped their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday.November 11, 2024 | marketbeat.comBuy Recommendation for Dianthus Therapeutics: Strong Financial Position and Promising Drug PipelineNovember 8, 2024 | markets.businessinsider.comDianthus Therapeutics Reports Q3 Progress and FinancialsNovember 8, 2024 | markets.businessinsider.comA Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 AnalystsNovember 8, 2024 | benzinga.comDianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $56.00Raymond James boosted their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an "outperform" rating in a report on Friday.November 8, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up - Still a Buy?Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up - Here's WhyNovember 8, 2024 | marketbeat.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial ResultsNovember 7, 2024 | globenewswire.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by AnalystsShares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have earned a consensus recommendation of "Buy" from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strongNovember 7, 2024 | marketbeat.comDianthus Therapeutics to Participate in Three Upcoming Healthcare Investor ConferencesNovember 4, 2024 | finance.yahoo.comDianthus Therapeutics to Participate in Three Upcoming Healthcare Investor ConferencesNovember 4, 2024 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5% - Should You Buy?Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 5% - Should You Buy?October 15, 2024 | marketbeat.comDianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual MeetingOctober 15, 2024 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.4% - Here's What HappenedDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.4% - Time to Sell?October 14, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Buy" from AnalystsShares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have received a consensus rating of "Buy" from the eleven analysts that are presently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation and two have givenOctober 13, 2024 | marketbeat.comDianthus: Modest Opportunity With 2 CaveatsOctober 9, 2024 | seekingalpha.comDianthus Therapeutics (NASDAQ:DNTH) Shares Up 4.5% - Still a Buy?Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 4.5% - What's Next?October 8, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume - Still a Buy?Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase - Still a Buy?October 4, 2024 | marketbeat.comOppenheimer Initiates Coverage of Dianthus Therapeutics (DNTH) with Outperform RecommendationOctober 4, 2024 | msn.comDianthus started at outperform by Oppenheimer on DNTH103 opportunityOctober 4, 2024 | seekingalpha.comDianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated by Analysts at OppenheimerOppenheimer initiated coverage on Dianthus Therapeutics in a research report on Thursday. They issued an "outperform" rating and a $48.00 price target on the stock.October 3, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. decreased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 50.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 174,200 shares of the company's stock after selling 17October 3, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down to $27.88Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down to $27.88October 2, 2024 | marketbeat.comFred Alger Management LLC Has $163,000 Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Fred Alger Management LLC cut its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 82.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,317 shares of the company's stock afSeptember 28, 2024 | marketbeat.comExpert Ratings For Dianthus TherapeuticsSeptember 26, 2024 | benzinga.comPromising Outlook for Dianthus Therapeutics’ DNTH103 as a Best-in-Class C1s InhibitorSeptember 26, 2024 | markets.businessinsider.comPoint72 Asia Singapore Pte. Ltd. Acquires 29,159 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Point72 Asia Singapore Pte. Ltd. grew its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 281.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,504 shares of the cSeptember 25, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Holdings Boosted by Great Point Partners LLCGreat Point Partners LLC lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 21.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 757,929 shares of the company'September 24, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.2%Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.2%September 23, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Up 7.5%Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.5%September 19, 2024 | marketbeat.comBank of New York Mellon Corp Has $2.10 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Bank of New York Mellon Corp boosted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 860.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 80,935 shares of the company's stock after purchaSeptember 18, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Buy" by BrokeragesShares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have received a consensus rating of "Buy" from the ten research firms that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and two have issued a stSeptember 18, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.3%Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.3%September 16, 2024 | marketbeat.comAtlas Venture Life Science Advisors LLC Decreases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Atlas Venture Life Science Advisors LLC reduced its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 26.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 136,979 shares of the company's stockSeptember 15, 2024 | marketbeat.comDianthus Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberSeptember 4, 2024 | finance.yahoo.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Increase in Short InterestDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the target of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 4,060,000 shares, a growth of 10.9% from the July 31st total of 3,660,000 shares. Based on an average daily volume of 271,200 shares, the days-to-cover ratio is currently 15.0 days. Approximately 20.2% of the shares of the company are sold short.September 1, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.7%Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.7%August 27, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Sees Strong Trading VolumeDianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeAugust 26, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Buy" from BrokeragesShares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been assigned an average recommendation of "Buy" from the ten analysts that are presently covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation and two haveAugust 24, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 9.6% in JulyDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totalling 3,660,000 shares, a growth of 9.6% from the July 15th total of 3,340,000 shares. Approximately 17.9% of the shares of the stock are sold short. Based on an average trading volume of 261,300 shares, the short-interest ratio is currently 14.0 days.August 19, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading 5.9% Higher Dianthus Therapeutics (NASDAQ:DNTH) Trading 5.9% HigherAugust 14, 2024 | marketbeat.comVanguard Group Inc. Has $16.14 Million Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Vanguard Group Inc. increased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 250.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 537,828 shares of the company's stockAugust 13, 2024 | marketbeat.comPromising Clinical Developments Bolster Buy Rating for Dianthus TherapeuticsAugust 12, 2024 | markets.businessinsider.comNavigating 4 Analyst Ratings For Dianthus TherapeuticsAugust 12, 2024 | benzinga.com Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. DNTH Media Mentions By Week DNTH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNTH News Sentiment▼0.060.45▲Average Medical News Sentiment DNTH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNTH Articles This Week▼82▲DNTH Articles Average Week Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amneal Pharmaceuticals News Scholar Rock News Zai Lab News Janux Therapeutics News Catalyst Pharmaceuticals News Iovance Biotherapeutics News Twist Bioscience News Longboard Pharmaceuticals News Arrowhead Pharmaceuticals News Protagonist Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNTH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts